Skip to content

Study · Animal study (in vivo) · rat · 2014

4 results

Noopept normalizes parameters of the incretin system in rats with experimental diabetes.

Ostrovskaya RU, Zolotov NN, Ozerova IV, Ivanova EA, Kapitsa IG, Taraban KV, Michunskaya AM, Voronina TA, Gudasheva TA, Seredenin SB

Bulletin of experimental biology and medicine1 Jul 2014Cited by 13 (Europe PMC)

PMID25065315 (opens in a new tab)DOI10.1007/s10517-014-2562-5 (opens in a new tab)PepBankPUB-25065315
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, oral Noopept had greater antihyperglycemic activity than intraperitoneal Noopept.

    In plain wordsIn rats with diabetes, oral Noopept reduced high blood glucose more than intraperitoneal Noopept.

    Peptide
    Noopept (omberacetam)
    Outcome
    IncreaseRoute-dependent antihyperglycemic activity
    Study

    ratn: not reported in source

    Adult Wistar rats with streptozotocin-induced diabetes
    Comparator
    Intraperitoneal Noopept
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (rat).

    Source sentences

    Summary
    Experiments on adult Wistar rats with streptozotocin-induced diabetes showed that antihyperglycemic activity of an original nootropic and neuroprotective drug Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is more pronounced under conditions of oral application than after intraperitoneal injection.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, Noopept normalized blood GLP-1 concentrations reduced by streptozotocin.

    In plain wordsIn rats with diabetes, Noopept normalized blood GLP-1 levels that streptozotocin had reduced.

    Peptide
    Noopept (omberacetam)
    Outcome
    IncreaseBlood GLP-1 concentration
    Study

    ratn: not reported in source

    Adult Wistar rats with streptozotocin-induced diabetes
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Noopept had a normalizing effect on these parameters.
    2 context sentences
    Summary · context
    Streptozotocin was shown to decrease the concentrations of incretin GLP-1 and insulin in the blood.
    Summary · context
    Experiments on adult Wistar rats with streptozotocin-induced diabetes showed that antihyperglycemic activity of an original nootropic and neuroprotective drug Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is more pronounced under conditions of oral application than after intraperitoneal injection.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, Noopept normalized blood insulin concentrations reduced by streptozotocin.

    In plain wordsIn rats with diabetes, Noopept normalized blood insulin levels that streptozotocin had reduced.

    Peptide
    Noopept (omberacetam)
    Outcome
    IncreaseBlood insulin concentration
    Study

    ratn: not reported in source

    Adult Wistar rats with streptozotocin-induced diabetes
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Noopept had a normalizing effect on these parameters.
    2 context sentences
    Summary · context
    Streptozotocin was shown to decrease the concentrations of incretin GLP-1 and insulin in the blood.
    Summary · context
    Experiments on adult Wistar rats with streptozotocin-induced diabetes showed that antihyperglycemic activity of an original nootropic and neuroprotective drug Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is more pronounced under conditions of oral application than after intraperitoneal injection.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In diabetic rats, Noopept's incretin-system effects were not related to dipeptidyl peptidase IV inhibition.

    In plain wordsIn rats with diabetes, Noopept's effects on incretins were not linked to inhibition of dipeptidyl peptidase IV.

    Peptide
    Noopept (omberacetam)
    Outcome
    Not applicableDipeptidyl peptidase IV inhibition
    Study

    ratn: not reported in source

    Adult Wistar rats with streptozotocin-induced diabetes
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This influence of Noopept was not related to the inhibition of a major enzyme metabolizing incretins (dipeptidyl peptidase IV).
    1 context sentence
    Summary · context
    Experiments on adult Wistar rats with streptozotocin-induced diabetes showed that antihyperglycemic activity of an original nootropic and neuroprotective drug Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is more pronounced under conditions of oral application than after intraperitoneal injection.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.